Search
Vargatef_Backgrounder.pdf
Corporate-Policy-on-Supply-Chain-Integrity_0.pdf
afatinib_backgrounder.pdf
Advancing_Anticoagulation_Care_Professor_Levy_Opinion_Piece.pdf
Afatinib_infographic.pdf
Boehringer_Ingelheim_consolidated_companies_2015.pdf
Boehringer_Ingelheim_Corporate_Factsheet.pdf
Praesentation_BPK_2017.pdf
Boehringer_Ingelheim_Consolidated_Companies_2016.pdf
Presentations_APC_2017.pdf
Online application
Online application | FAQ
Internal application
Internal applications | FAQ
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Combination Therapy
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
COPD Patient Survey Infographic
IT at BI
Discover firsthand what IT does at BI #IdoIT
Data Career
Data science at Boehringer Ingelheim is more than just solving fascinating problems. A chance to provide innovative solutions that bring value and hope to people.
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Spiriva® Respimat®
An add-on maintenance treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids.
Spiolto® Respimat®
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Striverdi® Respimat®
Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Combivent® Respimat®
A combination of a short-acting anticholinergic and beta-adrenergic for the management of reversible bronchospasms associated with obstructive airway diseases in patients requiring more than one bronchodilator.
Catapresan®
Treatment of hypertension.
Atrovent®
Prevention and treatment of shortness of breath in patients with chronic obstructive pulmonary disease (COPD) and mild to moderate bronchial asthma in adulthood and childhood as a supplement to beta-agonists in cases of acute asthma.